Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing

1 hour ago 2

Jake Lerch, The Motley Fool

Wed, March 4, 2026 astatine 10:11 AM CST 4 min read

Opaleye Management Inc. disclosed successful a February 17, 2026, SEC filing that it sold 180,000 shares of Liquidia (NASDAQ:LQDA), an estimated $5.12 cardinal commercialized based connected quarterly mean pricing.

According to a SEC filing dated February 17, 2026, Opaleye Management Inc. sold 180,000 shares of Liquidia during the 4th fourth of 2025. The estimated worth of the commercialized was astir $5.12 million, based connected the mean closing terms for the quarter. The money ended the play with 2,435,000 shares, with the quarter-end worth of the involvement expanding by $25.52 cardinal owed to some commercialized enactment and banal appreciation.

Opaleye Management Inc. trimmed its Liquidia position, which present accounts for 11.21% of reportable AUM.

Top holdings aft the filing:

NASDAQ:HROW: $191.34 cardinal (25.2% of AUM)
NASDAQ:LQDA: $84.98 cardinal (11.2% of AUM)
NASDAQ:ETON: $48.36 cardinal (6.4% of AUM)
NASDAQ:RYTM: $35.32 cardinal (4.7% of AUM)
NASDAQ:APGE: $29.31 cardinal (3.9% of AUM)

As of February 17, 2026, shares were priced astatine $33.84, up 105.7% implicit the past year, outperforming the S&P 500 by 97.0 percent points.

Metric

Value

Price (as of marketplace adjacent 2/17/26)	$33.84
Market capitalization	$2.94 billion
Revenue (TTM)	$69.22 million
Net income (TTM)	($121.85 million)

Products see YUTREPIA, an inhaled adust pulverization formulation of treprostinil for pulmonary arterial hypertension, and organisation of generic treprostinil injection successful the United States.
Revenue is chiefly generated done the development, manufacturing, and commercialization of proprietary and generic therapies targeting unmet needs successful pulmonary arterial hypertension.
The institution targets healthcare providers and patients successful the United States requiring precocious therapies for pulmonary arterial hypertension and related conditions.

Liquidia is simply a biopharmaceutical institution focused connected innovative therapies for pulmonary arterial hypertension, leveraging proprietary cause transportation technologies. The company's strategy centers connected addressing unmet aesculapian needs done differentiated merchandise formulations and expanding its portfolio successful the United States market. Liquidia's competitory vantage lies successful its specialized expertise successful inhaled cause transportation and its quality to commercialize some branded and generic therapies wrong a highly regulated sector.

Opaleye Management, a Massachusetts-based concern manager, precocious disclosed a merchantability of astir $5.1 cardinal worthy of Liquidia stock. Here’s however investors whitethorn privation to deliberation astir it.

Read Entire Article